Eli Lilly and Company
LLY
$660.49
$21.063.29%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.66B | 2.76B | 4.41B | 970.30M | 2.97B |
| Total Depreciation and Amortization | 478.50M | 462.80M | 484.80M | 466.80M | 414.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -789.20M | 1.81B | -195.90M | 2.28B | -516.10M |
| Change in Net Operating Assets | -2.26B | -3.36B | -2.22B | -9.80M | -1.40B |
| Cash from Operations | 3.09B | 1.67B | 2.47B | 3.71B | 1.47B |
| Capital Expenditure | -1.70B | -1.51B | -1.50B | -1.35B | -1.22B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | 0.00 | -947.70M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -137.80M | -1.84B | -424.50M | -2.65B | -26.20M |
| Cash from Investing | -1.83B | -3.35B | -1.92B | -4.00B | -2.20B |
| Total Debt Issued | 0.00 | 6.46B | 0.00 | 4.96B | 0.00 |
| Total Debt Repaid | 824.70M | -1.85B | 3.04B | -3.09B | 2.74B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -692.20M | -1.20B | -2.05B | -446.10M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.35B | -1.35B | -1.17B | -1.17B | -1.17B |
| Other Financing Activities | -30.40M | -686.30M | -45.50M | -47.30M | -8.00M |
| Cash from Financing | -1.24B | 1.38B | -225.40M | 211.30M | 1.56B |
| Foreign Exchange rate Adjustments | 275.50M | 131.90M | -428.50M | 226.90M | -59.60M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 282.60M | -175.10M | -100.60M | 145.40M | 763.40M |